EGFR and intrahepatic cholangiocarcinoma: This regulatory process operates through two sequential mechanisms: (1) METTL1 deficiency decreases m7G-modified tRNA (e.g., LysCTT) abundance, inducing ribosome stalling at high-frequency codons (e.g., AAG) and preferentially suppressing translation of codon-enriched oncogenic transcripts like Cyclin-A2 (CCNA2) and Epidermal Growth Factor Receptor (EGFR); (2) Resultant translational repression reduces protein expression of cell cycle regulators (CCNA2, CDK6) and EGFR signaling components (EGFR, AKT, mTOR), ultimately inhibiting ICC proliferation and invasion (29).